Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Monoferric | Iron (III) Isomaltoside 1000 | iron deficiency anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Monoprost | latanoprost | glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Movapo | apomorphine hydrochloride | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Mozobil | Plerixafor | Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma | Do not list | Complete | ||
| Multaq | Dronedarone hydrochloride | Atrial fibrillation | Do not list | Complete | ||
| Mvasi | Bevacizumab | mCRC NSCLC Biosimilar | N/A | Complete | ||
| Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Reimburse with clinical criteria and/or conditions | Active | ||
| Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | ||
| Myinfla | colchicine | Atherothrombotic events in coronary artery disease | Do not reimburse | Complete | ||
| Mylotarg | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia (AML) | Reimburse | Complete |
Last Updated : July 28, 2024